Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

Halberd Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon May 09, 2023 8:01am
29 Views
Post# 35438027

New Press Release - Halberd Pre-Clinical Test Protocol Approved

New Press Release - Halberd Pre-Clinical Test Protocol Approved
Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's EndJACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities